Location History:
- Dossenheim, DE (2013)
- Heidelberg, DE (2017 - 2018)
Company Filing History:
2 out of 155 
2 out of 23 
1 out of 160 
Years Active: 2013-2018
Title: The Innovative Contributions of Laurent Daeffler
Introduction
Laurent Daeffler is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches involving parvoviruses and cytokines. With a total of 3 patents, Daeffler's work is paving the way for new treatment methodologies in oncology.
Latest Patents
Daeffler's latest patents include groundbreaking inventions aimed at improving cancer treatment. One of his notable patents is the "Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer." This invention focuses on the combination of a parvovirus and a cytokine, preferably IFN, to treat pancreatic cancer, especially in its terminal stages. Another significant patent is titled "Methods of treating cancer using chemovirotherapy." This patent describes a diagnostic method for predicting a patient's response to chemovirotherapy or radiovirotherapy. It involves exposing primary tumor cells from patients, such as those from brain tumors or pancreatic cancer, to a parvovirus and/or a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.
Career Highlights
Throughout his career, Laurent Daeffler has worked with esteemed institutions, including the Deutsches Krebsforschungszentrum and Ruprecht-Karls-Universität Heidelberg. His work in these organizations has allowed him to focus on innovative cancer therapies and collaborate with leading experts in the field.
Collaborations
Daeffler has collaborated with notable colleagues such as Jean Rommelaere and Zahari Raykov. These partnerships have contributed to the advancement of his research and the development of his patents.
Conclusion
Laurent Daeffler's contributions to cancer therapy through his innovative patents highlight his commitment to improving patient outcomes. His work continues to inspire advancements in the field of oncology.